Open AccessEvaluation of allergenic properties and immunotoxicity tablet dosage form GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazin-3-carboxamide)
Author(s) -
Л. П. Коваленко,
К. В. Коржова,
Р. В. Журиков,
Андрей Дмитриевич Дурнев
Publication year - 2020
Publication title -
farmakokinetika i farmakodinamika
Language(s) - English
Resource type - Journals
eISSN - 2686-8830
pISSN - 2587-7836
DOI - 10.37489/2587-7836-2020-2-34-36
Subject(s) - pharmacology , chemistry , toxicity , traditional medicine , medicine , organic chemistry
The study of allergenic properties and immunotoxic effects of the ready-to-use drug form of GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazin-3-carboxamide), compounds with high TSPO affinity and pronounced anxiolytic activity, was carried out. The study of allergenic properties and immunotoxicity of GML-1 was performed on male albino guinea pigs weighing 250-300 g and on male CBA, C57BL / 6, F1 hybrids (CBAxC57BL/6) mice. When assessing immunotoxicity, GML-1 was inject to mice per os for 14 days in doses of 2.2 mg / kg and 22 mg / kg. When studying the allergenicity, GML-1 was injected to albino guinea pigs in doses of 1 mg / kg and 10 mg / kg according to standard regimens of immunization. The results of the study of the immuno-toxicity and allergenicity of GML-1 allow us to conclude that the injection of tablet dosage form of GML-1 in the range of studied doses does not have an immunotoxic effect and allergenic properties.